[Reporter’s Notebook] Drug policy: focus on the ‘how,’ not just ‘how much’

Recent policy debates in the pharmaceutical and medical sectors have all revolved around one thing: drugs. Policies such as prescribing by generic name, promoting substitution at the pharmacy, and cutting prices for generics may look different on the surface, but they all point in the same direction: lowering drug prices.
Under a generic-name prescription system, doctors write only the active ingredient instead of a specific brand, and pharmacists choose one of the medicines that contain that ingredient. If substitution at the pharmacy is further encouraged, patients can be switched to cheaper medicines at the dispensing stage. As the country enters a super-aged society and pressure on the national health insurance budget grows, the policy rationale of saving public funds and easing patients’ financial burden is clear.
The problem is the gap in how this is felt on the ground. The medical community worries about continuity of care and who bears responsibility. Even with the same ingredient, formulation, absorption rate, and patient response can differ, and for people with chronic diseases or older patients, small differences can translate into different clinical outcomes. The pharmacy sector, for its part, warns that in a system dominated by generics, excessive price competition could weaken companies’ capacity to maintain quality control.
On top of this, the push to cut generic drug prices has further intensified conflict. As the system that sets generics at a fixed percentage of the original drug’s price is tightened, industry resistance has grown. Pharmaceutical companies have repeatedly argued that steep price cuts could, over the long term, lead to supply instability or a decline in quality.
There is, of course, a counterargument. Critics say the domestic drug market has become overly complex, with many products sharing the same ingredient but sold at different prices, and that unnecessary costs have piled up in the process.
From a patient’s perspective, it is understandably hard to accept why they should pay more for a drug that delivers the same therapeutic effect.
In the end, the key is balance. Drug pricing policy cannot stop at making medicines simply cheaper. It must also take into account patient safety in treatment, doctors’ prescribing authority, pharmacists’ professional role in dispensing, and the long-term viability of pharmaceutical companies. If any one of these pillars is shaken, the burden will ultimately fall back on patients.
Speed is another issue. Debate over drug pricing is nothing new, but the recent pace feels somewhat hasty. Compared with the clear goal of cutting costs, it is fair to ask whether there has been enough review of the variables that could arise in real-world settings.
Medicine is not an ordinary consumer good. Its impact is too broad and deep to be treated solely through the lens of price competition. What matters is not only "how much" prices are reduced, but "how" to reduce them without causing the system to collapse. What is needed now is not speed, but careful and sophisticated policy design.
vrdw88@fnnews.com Kang Jung-mo, Ministry of SMEs and Startups (MSS) Reporter